① Yuexiu Real Estate's contract sales in the first quarter fell by more than 50% year on year. How did other real estate companies monetize?
② CGN New Energy's photovoltaic power generation increased by 18% during the year. What are the highlights of other businesses?
The important announcements for Hong Kong stocks yesterday are as follows:
Operational data
$YUEXIU PROPERTY (00123.HK)$: In the first 3 months, cumulative contract sales amounted to RMB 21.702 billion, a year-on-year decrease of about 50.5%.
$LONGFOR GROUP (00960.HK)$: In the first 3 months, cumulative contract sales amounted to 23.48 billion yuan, a year-on-year decrease of 53.7%.
$YUZHOU GROUP (01628.HK)$: In the first 3 months, the total contract sales were 2,208 billion yuan, with an average price of 15,744 yuan.
$YUE YUEN IND (00551.HK)$: The consolidated cumulative net operating income for the first quarter was US$2.03 billion, a year-on-year decrease of 4.94%.
$POU SHENG INT'L (03813.HK)$: The consolidated cumulative net operating revenue for the first quarter was 5.4 billion yuan, down 7.5% year on year.
$CGN NEW ENERGY (01811.HK)$: A total of 4956.7 gigawatt-hours of power generation was completed in the first 3 months, an increase of 0.3% over 2023. Among them, China's wind power projects increased by 4.4%, China's solar energy projects increased by 18.1%, China's cogeneration and gas projects increased by 8.2%, China's hydropower projects increased by 3.9%, and South Korea's projects decreased by 10.4%.
$WASION HOLDINGS (03393.HK)$: Weisheng Group, a subsidiary of the company, won contracts for about 899,000 smart meters from the State Grid, with a contract value of approximately RMB 306 million. In addition, Weisheng Information Technology Co., Ltd. also won contracts for approximately 56,000 data collection terminals and concentrators, with a contract value of approximately RMB 106 million.
Pharmaceutical Innovation
$SINO BIOPHARM (01177.HK)$: Three innovative drugs announced six research results at AACR
$SH PHARMA (02607.HK)$: Rabeprazole sodium enteric tablets passed generic drug consistency evaluation
$SHANDONG XINHUA (00719.HK)$: Cefaclor capsules passed generic drug consistency evaluation
Buyback News
$PAGODA GP (02411.HK)$: A number of controlling shareholders who collectively control about 693 million shares of the company made voluntary sales bans until April 10, 2025. The shares involved are equivalent to approximately 43.64% of the company's total registered share capital.
$TENCENT (00700.HK)$: A repurchase of 3.2 million shares was spent at HK$1,001 billion, with a repurchase price of HK$307-315.2 per share.
$MEITUAN-W (03690.HK)$: Approximately HK$400 million was spent to repurchase 3.8817 million shares at a repurchase price of HK$99.7-104.7 per share.
$HSBC HOLDINGS (00005.HK)$: HK$300 million was spent to repurchase 4.7 million shares at a repurchase price of HK$63.7-64.1 per share.
$TUHU-W (09690.HK)$: Spend HK$357.215 million to repurchase 2 million shares at a repurchase price of HK$17.6-17.98 per share.
$CK ASSET (01113.HK)$: 752,500 shares were repurchased at HK$24.528,600 at a repurchase price of HK$32.45 to HK$32.65 per share.
$SWIRE PACIFIC A (00019.HK)$: A repurchase of 193,000 shares was spent at HK$12.258,300, at a repurchase price of HK$62.9-HK$64.25 per share.
edit/new